MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer EV/EBITDA Ratio 2011-2026 | PKI
Annual EV/EBITDA Ratio PerkinElmer
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 18.8 | - | 23.4 | 22 | 16.3 | 17.2 | - | 17.8 | 16.1 | 17.4 | 32.1 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.1 | 16.1 | 20.1 |
EV/EBITDA Ratio of other stocks in the Diagnostics research industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
27.4 | $ 111.3 | -3.12 % | $ 33.8 B |  USA |
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
55.6 | $ 25.58 | -5.68 % | $ 20 B |  Niderland |
 |
CareDx, Inc
CDNA
|
-100 | $ 20.8 | -5.07 % | $ 1.11 B | USA |
 |
Chembio Diagnostics
CEMI
|
-1.23 | - | 0.22 % | $ 16.8 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M |  Britain |
 |
Check-Cap Ltd.
CHEK
|
-0.674 | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
3.62 | $ 1.53 | -6.13 % | $ 2.04 M | USA |
 |
Castle Biosciences
CSTL
|
-21.2 | $ 24.24 | -1.86 % | $ 673 M | USA |
 |
DermTech
DMTK
|
-2.44 | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
22 | $ 163.84 | -1.77 % | $ 8.12 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | USA |
 |
Enzo Biochem
ENZ
|
58.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-20.8 | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-28.8 | $ 83.41 | 0.35 % | $ 10.5 B | USA |
 |
Fulgent Genetics
FLGT
|
2.58 | $ 14.8 | -3.27 % | $ 447 M | USA |
 |
Heska Corporation
HSKA
|
141 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-1.42 | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
-6.02 | $ 1.99 | 2.9 % | $ 8.8 M | USA |
 |
Illumina
ILMN
|
70.5 | $ 120.37 | -5.16 % | $ 19.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
13.2 | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
-6.24 | $ 2.16 | -1.22 % | $ 4.96 M | USA |
 |
Lantheus Holdings
LNTH
|
-187 | $ 81.17 | -2.85 % | $ 5.48 B | USA |
 |
ICON Public Limited Company
ICLR
|
38 | $ 116.17 | 13.35 % | $ 9.58 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.7 | $ 257.14 | -0.94 % | $ 21.4 B | USA |
 |
Medpace Holdings
MEDP
|
30.7 | $ 413.59 | 0.93 % | $ 11.9 B | USA |
 |
Celcuity
CELC
|
-2.38 | $ 119.0 | -0.89 % | $ 5.56 B | USA |
 |
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | Israel |
 |
NeoGenomics
NEO
|
-33.5 | $ 8.96 | -0.67 % | $ 1.15 B | USA |
 |
Neogen Corporation
NEOG
|
40.3 | $ 9.01 | -3.53 % | $ 1.95 B | USA |
 |
National Research Corporation
NRC
|
21 | $ 16.54 | -1.78 % | $ 370 M | USA |
 |
Invitae Corporation
NVTA
|
-10.7 | - | - | $ 21.2 M | USA |
 |
Myriad Genetics
MYGN
|
-17.2 | $ 4.68 | -3.31 % | $ 433 M | USA |
 |
OpGen
OPGN
|
0.274 | - | -16.95 % | $ 1.54 M | USA |
 |
Natera
NTRA
|
-19.5 | $ 194.75 | -2.71 % | $ 19.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.51 | $ 189.32 | -2.94 % | $ 21 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-1.51 | $ 16.24 | -2.46 % | $ 175 M | China |
 |
Organovo Holdings
ONVO
|
0.992 | - | -2.3 % | $ 19.4 M | USA |
 |
Personalis
PSNL
|
-7.07 | $ 5.04 | -8.36 % | $ 299 M | USA |
 |
Precipio
PRPO
|
-1.8 | $ 29.94 | -5.73 % | $ 48.1 M | USA |
 |
Exagen
XGN
|
-2.2 | $ 2.76 | 1.1 % | $ 59.5 M | USA |